presentación de powerpoint · 2019-06-28 · d i s e a s e-f r e e s u r v i v a l r a t e 0 .0 0...
TRANSCRIPT
S-TRACT
Dis
ease-f
ree s
urv
ival ra
te
0.00
0
0.20
0.40
0.60
0.80
1.00
6 12 18 24 30 36 42 54 60
Pazopanib (n=198)
Placebo (n=205)
HR (95% CI): 0.69 (0.51, 0.94)
Log-rank P-value = 0.02
198
205
Patients at risk
Pazopanib
Placebo
Months since randomization
176
169
156
144
140
134
128
119
123
106
113
97
102
85
8
3
0
0
48
48
46
ITT 800 mg
Dis
ease-f
ree s
urv
ival ra
te
0.00
0
0.20
0.40
0.60
0.80
1.00
6 12 18 24 30 36 42 54 60
Pazopanib (n=769)
Placebo (n=769)
HR (95% CI): 0.80 (0.68, 0.95)
Log-rank P-value = 0.01
769
769
Patients at risk
Pazopanib
Placebo
Months since randomization
658
612
579
538
522
506
436
419
332
319
231
215
131
122
8
3
0
0
48
48
46
ITT All
Dis
ease-f
ree s
urv
ival ra
te
0.00
0
0.20
0.40
0.60
0.80
1.00
6 12 18 24 30 36 42 54 60
Pazopanib (n=198)
Placebo (n=205)
HR (95% CI): 0.69 (0.51, 0.94)
Log-rank P-value = 0.02
198
205
Patients at risk
Pazopanib
Placebo
Months since randomization
176
169
156
144
140
134
128
119
123
106
113
97
102
85
8
3
0
0
48
48
46
ITT 800 mg
Dis
ease-f
ree s
urv
ival ra
te
0.00
0
0.20
0.40
0.60
0.80
1.00
6 12 18 24 30 36 42 54 60
Pazopanib (n=769)
Placebo (n=769)
HR (95% CI): 0.80 (0.68, 0.95)
Log-rank P-value = 0.01
769
769
Patients at risk
Pazopanib
Placebo
Months since randomization
658
612
579
538
522
506
436
419
332
319
231
215
131
122
8
3
0
0
48
48
46
ITT All
PROTECT
ASSURE
FuhrmanGrade
ECOG PS
UISS Risk
TNM(or AJCC)
Stage
Nodal disease
T1 T3 T4
Grade 1–2
Grade 3–4
Grade1
Grade2–4
ECOG≥1
ECOG 0
ECOG≥1
Intermediate risk
High risk
Low risk
ECOG 0
Grade1–4
ECOGany
01+
T2
Grade 3–4
ECOG any
Grade 1–2
N Stage
T Stage
ASSURE PROTECT S-TRAC
